Lab
East Side Clinical Laboratory, INC.
East Side Clinical Laboratory, INC. was paid $48.64M by Medicaid between Jan 2018 and Dec 2024, across 295 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 12% of everything it billed.
33Billing provider infoEAST SIDE CLINICAL LABORATORY, INC.
EAST PROVIDENCE, RI 02914
EAST PROVIDENCE, RI 02914
33aNPI1861404121assigned 08/13/2006
33bProvider typeClinical Medical Laboratory
28Total paid$48.64M
24GClaims3,627,098
24DCodes billed295
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Rhode Island
Rank by total paid#2 of 6
Median peer was paid$1.49M
This provider vs. median33×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 629,095 | $7.41M | |
| 2019 | 562,799 | $5.53M | |
| 2020 | 411,481 | $5.30M | |
| 2021 | 556,813 | $8.46M | |
| 2022 | 531,695 | $8.45M | |
| 2023 | 498,831 | $7.10M | |
| 2024incomplete | 436,384 | $6.40M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 12% | 80,817 | 55,619 | $5.66M |
| 80050 | General health panel | 10% | 105,818 | 91,132 | $5.07M |
| 80061 | Lipid panel | 5.6% | 198,951 | 172,762 | $2.74M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.9% | 87,172 | 75,656 | $2.38M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.2% | 35,546 | 30,295 | $1.58M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 237,969 | 174,398 | $1.38M |
| 80053 | Comprehensive metabolic panel | 2.5% | 144,149 | 118,514 | $1.20M |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.3% | 136,915 | 119,255 | $1.12M |
| 84443 | Thyroid stimulating hormone (TSH) | 2.3% | 85,287 | 73,837 | $1.10M |
| 36415 | Collection of venous blood by venipuncture | 2.2% | 303,829 | 187,573 | $1.08M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.1% | 26,341 | 22,710 | $1.03M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.1% | 26,120 | 22,041 | $1.02M |
283 more codes
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.8% | 50,145 | $871K |
| 86480 | 1.6% | 16,366 | $768K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.5% | 16,903 | $742K |
| 86803 | 1.4% | 50,902 | $686K | |
| 86003 | 1.4% | 7,512 | $671K | |
| 82607 | 1.3% | 47,442 | $637K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 16,483 | $581K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 112,370 | $564K |
| 82728 | 1.1% | 38,051 | $515K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.0% | 3,613 | $502K |
| 87522 | Neg quan hep c or qual rna | 1.0% | 10,382 | $489K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 89,610 | $480K |
| 84439 | <1% | 48,730 | $449K | |
| 85027 | <1% | 63,236 | $371K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 16,713 | $348K |
| 87902 | <1% | 1,684 | $344K | |
| 83013 | <1% | 4,513 | $344K | |
| 84403 | <1% | 11,077 | $308K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 103,701 | $298K |
| 84481 | <1% | 33,511 | $292K | |
| 80076 | <1% | 46,226 | $289K | |
| 81001 | <1% | 86,846 | $281K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,716 | $280K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,485 | $265K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,503 | $264K |
| 82043 | <1% | 39,902 | $263K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,743 | $261K |
| 86706 | <1% | 22,557 | $238K | |
| 82652 | <1% | 5,507 | $236K | |
| 86780 | <1% | 21,243 | $233K | |
| 84153 | <1% | 13,949 | $233K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 7,410 | $227K |
| 82570 | <1% | 43,690 | $209K | |
| 80074 | <1% | 4,181 | $205K | |
| 83550 | <1% | 25,246 | $201K | |
| 86618 | <1% | 9,905 | $194K | |
| 82746 | <1% | 20,649 | $189K | |
| 83970 | <1% | 5,666 | $188K | |
| 83516 | <1% | 8,032 | $187K | |
| 87186 | <1% | 26,201 | $177K | |
| 87070 | <1% | 18,288 | $172K | |
| 87340 | <1% | 15,604 | $172K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 906 | $170K |
| 83880 | <1% | 10,858 | $161K | |
| 88112 | <1% | 2,284 | $159K | |
| 86038 | <1% | 11,850 | $159K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,025 | $147K |
| 84402 | <1% | 5,878 | $139K | |
| 84146 | <1% | 6,672 | $134K | |
| 86762 | <1% | 8,245 | $128K | |
| 86704 | <1% | 10,452 | $127K | |
| 83540 | <1% | 17,816 | $123K | |
| 86617 | <1% | 3,529 | $123K | |
| 86787 | <1% | 8,377 | $120K | |
| 86769 | <1% | 2,992 | $119K | |
| 84460 | <1% | 24,649 | $117K | |
| 87338 | <1% | 5,899 | $116K | |
| 83001 | <1% | 5,582 | $115K | |
| 86140 | <1% | 25,351 | $112K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,695 | $108K |
| 84702 | <1% | 6,090 | $106K | |
| 83735 | <1% | 24,254 | $105K | |
| 86665 | <1% | 2,932 | $105K | |
| 84450 | <1% | 21,752 | $104K | |
| 87088 | <1% | 16,948 | $104K | |
| 85652 | <1% | 34,007 | $101K | |
| 82670 | <1% | 3,409 | $101K | |
| 86317 | <1% | 1,462 | $101K | |
| 86765 | <1% | 7,294 | $101K | |
| 86735 | <1% | 7,218 | $100K | |
| 86708 | <1% | 9,470 | $96K | |
| 86696 | <1% | 4,213 | $94K | |
| 85610 | <1% | 52,862 | $92K | |
| 87467 | <1% | 5,109 | $92K | |
| 82274 | <1% | 6,786 | $89K | |
| 82550 | <1% | 14,201 | $87K | |
| 86709 | <1% | 5,997 | $87K | |
| 82784 | <1% | 5,147 | $80K | |
| 83002 | <1% | 3,892 | $78K | |
| 83690 | <1% | 10,640 | $77K | |
| 86200 | <1% | 3,440 | $73K | |
| 87510 | <1% | 3,014 | $73K | |
| 87480 | <1% | 3,007 | $72K | |
| 84207 | <1% | 2,491 | $71K | |
| 87660 | <1% | 2,857 | $70K | |
| 82565 | <1% | 16,971 | $69K | |
| 83721 | <1% | 11,395 | $68K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 5,127 | $66K |
| 87209 | <1% | 3,084 | $64K | |
| 84154 | <1% | 3,260 | $61K | |
| 82150 | <1% | 8,530 | $58K | |
| 85007 | <1% | 18,590 | $57K | |
| 87077 | <1% | 8,950 | $56K | |
| 84445 | <1% | 913 | $53K | |
| 87427 | <1% | 2,154 | $53K | |
| 83020 | <1% | 3,523 | $51K | |
| 86695 | <1% | 3,701 | $50K | |
| 82785 | <1% | 2,841 | $47K | |
| 80164 | <1% | 6,360 | $46K | |
| 80051 | <1% | 8,486 | $46K | |
| 82248 | <1% | 11,485 | $46K | |
| 86376 | <1% | 2,873 | $45K | |
| 86664 | <1% | 2,876 | $45K | |
| 84550 | <1% | 11,237 | $44K | |
| 82627 | <1% | 1,791 | $44K | |
| 87536 | <1% | 481 | $42K | |
| 84480 | <1% | 3,270 | $42K | |
| 84484 | <1% | 3,152 | $41K | |
| 82947 | <1% | 10,668 | $40K | |
| 84252 | <1% | 1,632 | $40K | |
| 86663 | <1% | 2,889 | $40K | |
| 84134 | <1% | 6,346 | $39K | |
| 82140 | <1% | 5,766 | $39K | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 91,650 | $39K |
| 87046 | <1% | 2,182 | $39K | |
| 86705 | <1% | 2,587 | $37K | |
| 84100 | <1% | 9,819 | $36K | |
| 86430 | <1% | 5,517 | $35K | |
| 85379 | <1% | 6,866 | $35K | |
| ATP14 | <1% | 5,515 | $34K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 213 | $34K |
| 84703 | <1% | 3,952 | $34K | |
| 84436 | <1% | 6,735 | $33K | |
| 86694 | <1% | 2,094 | $33K | |
| 83525 | <1% | 2,505 | $32K | |
| 87481 | <1% | 386 | $31K | |
| 82105 | <1% | 2,228 | $31K | |
| 84520 | <1% | 10,768 | $31K | |
| 82465 | <1% | 5,955 | $31K | |
| 87625 | <1% | 1,233 | $30K | |
| 86256 | <1% | 1,227 | $30K | |
| 85018 | <1% | 12,675 | $30K | |
| 86666 | <1% | 818 | $28K | |
| 84165 | <1% | 2,339 | $28K | |
| 84425 | <1% | 3,548 | $28K | |
| 86160 | <1% | 1,069 | $28K | |
| 82533 | <1% | 1,560 | $26K | |
| 87045 | <1% | 2,804 | $26K | |
| 82977 | <1% | 3,702 | $26K | |
| 84075 | <1% | 5,079 | $25K | |
| 84466 | <1% | 2,124 | $25K | |
| 81003 | <1% | 10,064 | $24K | |
| 82024 | <1% | 598 | $24K | |
| 86235 | <1% | 1,099 | $24K | |
| 86141 | <1% | 2,017 | $23K | |
| 87529 | <1% | 327 | $23K | |
| 87177 | <1% | 3,051 | $23K | |
| 85730 | <1% | 3,772 | $23K | |
| 86225 | <1% | 1,454 | $23K | |
| 84590 | <1% | 1,793 | $23K | |
| 87511 | <1% | 695 | $22K | |
| 86800 | <1% | 1,364 | $22K | |
| 84144 | <1% | 1,039 | $22K | |
| 80178 | <1% | 3,717 | $21K | |
| 83921 | <1% | 1,210 | $21K | |
| 82103 | <1% | 1,414 | $21K | |
| 87205 | <1% | 4,892 | $20K | |
| 83993 | <1% | 777 | $19K | |
| 83090 | <1% | 682 | $18K | |
| 81000 | <1% | 4,807 | $18K | |
| 83520 | <1% | 1,206 | $18K | |
| 84156 | <1% | 2,998 | $17K | |
| 82247 | <1% | 3,519 | $17K | |
| 80069 | <1% | 2,162 | $17K | |
| 83615 | <1% | 3,498 | $17K | |
| 87517 | <1% | 369 | $17K | |
| 82955 | <1% | 2,201 | $17K | |
| 85045 | <1% | 3,513 | $17K | |
| 84270 | <1% | 702 | $17K | |
| 86677 | <1% | 676 | $16K | |
| 87469 | <1% | 303 | $16K | |
| 83498 | <1% | 459 | $16K | |
| 87484 | <1% | 267 | $15K | |
| 82040 | <1% | 5,757 | $15K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 58,877 | $15K |
| 81025 | <1% | 2,132 | $15K | |
| 80159 | <1% | 1,127 | $14K | |
| 86431 | <1% | 2,164 | $14K | |
| 80177 | <1% | 2,208 | $14K | |
| 84132 | <1% | 4,333 | $13K | |
| 86334 | <1% | 603 | $12K | |
| 82310 | <1% | 2,640 | $12K | |
| 86901 | <1% | 2,130 | $12K | |
| 86308 | <1% | 2,023 | $12K | |
| 87255 | <1% | 241 | $11K | |
| 85014 | <1% | 6,013 | $11K | |
| 84145 | <1% | 1,632 | $11K | |
| 83655 | <1% | 1,542 | $11K | |
| 82553 | <1% | 1,038 | $11K | |
| 87634 | <1% | 254 | $11K | |
| 82747 | <1% | 680 | $10K | |
| 83519 | <1% | 615 | $10K | |
| 84181 | <1% | 384 | $9K | |
| ATP07 | <1% | 1,277 | $9K | |
| 86039 | <1% | 636 | $9K | |
| 88304 | <1% | 233 | $9K | |
| 84155 | <1% | 2,514 | $9K | |
| 86900 | <1% | 2,035 | $9K | |
| 86850 | <1% | 1,540 | $9K | |
| 87081 | <1% | 1,589 | $8K | |
| 87324 | <1% | 581 | $8K | |
| 80202 | <1% | 970 | $8K | |
| 87468 | <1% | 298 | $8K | |
| 82390 | <1% | 715 | $8K | |
| 87449 | <1% | 722 | $8K | |
| 84305 | <1% | 324 | $8K | |
| 86753 | <1% | 388 | $8K | |
| 84479 | <1% | 1,337 | $8K | |
| 87476 | <1% | 162 | $7K | |
| 84630 | <1% | 572 | $7K | |
| 87478 | <1% | 252 | $7K | |
| 80047 | <1% | 787 | $7K | |
| 87328 | <1% | 326 | $7K | |
| 83718 | <1% | 717 | $7K | |
| 82330 | <1% | 1,111 | $6K | |
| ATP08 | <1% | 1,210 | $6K | |
| 86255 | <1% | 330 | $5K | |
| 87400 | <1% | 350 | $5K | |
| 86592 | <1% | 1,195 | $5K | |
| 84681 | <1% | 225 | $5K | |
| 83883 | <1% | 332 | $4K | |
| 88312 | <1% | 85 | $4K | |
| 84478 | <1% | 863 | $4K | |
| 82950 | <1% | 935 | $4K | |
| 87073 | <1% | 423 | $4K | |
| ATP15 | <1% | 694 | $4K | |
| ATP03 | <1% | 580 | $4K | |
| 83010 | <1% | 368 | $3K | |
| 82172 | <1% | 161 | $3K | |
| 84166 | <1% | 147 | $3K | |
| 80156 | <1% | 287 | $3K | |
| 82552 | <1% | 211 | $3K | |
| 81015 | <1% | 769 | $3K | |
| ATP17 | <1% | 768 | $2K | |
| 80185 | <1% | 273 | $2K | |
| 82270 | <1% | 673 | $2K | |
| 85245 | <1% | 66 | $2K | |
| 86147 | <1% | 27 | $2K | |
| 84432 | <1% | 112 | $2K | |
| 82088 | <1% | 30 | $2K | |
| 82525 | <1% | 117 | $2K | |
| 82378 | <1% | 172 | $2K | |
| 86747 | <1% | 106 | $2K | |
| 85246 | <1% | 52 | $1K | |
| 85240 | <1% | 62 | $1K | |
| 86341 | <1% | 37 | $1K | |
| 87040 | <1% | 187 | $1K | |
| 82653 | <1% | 38 | $1K | |
| 82626 | <1% | 43 | $994.69 | |
| 82157 | <1% | 25 | $965.18 | |
| 84080 | <1% | 63 | $880.71 | |
| ATP16 | <1% | 116 | $838.53 | |
| 84295 | <1% | 191 | $835.42 | |
| 86060 | <1% | 98 | $832.66 | |
| 88311 | <1% | 80 | $785.23 | |
| 85048 | <1% | 262 | $780.55 | |
| 84244 | <1% | 29 | $762.12 | |
| 86645 | <1% | 51 | $715.68 | |
| 82951 | <1% | 39 | $608.29 | |
| 82671 | <1% | 15 | $474.12 | |
| 86682 | <1% | 26 | $427.16 | |
| 82397 | <1% | 12 | $422.12 | |
| ATP11 | <1% | 57 | $382.62 | |
| 87350 | <1% | 29 | $364.32 | |
| 83605 | <1% | 27 | $342.25 | |
| 86162 | <1% | 14 | $313.43 | |
| 83835 | <1% | 15 | $292.65 | |
| 86644 | <1% | 17 | $283.81 | |
| 86707 | <1% | 12 | $244.40 | |
| 83695 | <1% | 12 | $220.85 | |
| ATP18 | <1% | 97 | $208.43 | |
| 82104 | <1% | 12 | $207.92 | |
| 86215 | <1% | 12 | $176.22 | |
| 85049 | <1% | 34 | $164.66 | |
| 84300 | <1% | 24 | $130.92 | |
| 87101 | <1% | 12 | $119.14 | |
| 85660 | <1% | 12 | $68.23 | |
| 83935 | <1% | 18 | $57.70 | |
| ATP13 | <1% | 34 | $43.56 | |
| ATP19 | 0% | 30 | $0.00 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 0% | 12 | $0.00 |
| U00O3 | 0% | 58 | $0.00 | |
| 80301 | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGREENBERG, ALAN (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Sunrise Medical Laboratories, INC. | Hicksville, NY | $101.48M |
| Innovation Optics | Roselle Park, NJ | $269K |
| Innovative Eyewear | Short Hills, NJ | $7K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.